Skip to main content

Table 6 Summary of adverse reactions in each treatment group

From: Safety and efficacy of curcumin versus diclofenac in knee osteoarthritis: a randomized open-label parallel-arm study

Adverse reactions

Curcumina

(N = 70)

Diclofenacb

(N = 69)

RR

RRLB

RRUB

NNT

n (%)

n (%)

    

Total number of patients experiencing AEs*

9 (13%)

26 (38%)

    

Dyspepsia

0

6 (8.7%)

0.08**

0

1.3

12

Nausea

6 (9%)

7 (10.14%)

0.8

0.3

2.4

64

Vomiting

0

7 (10.14%)

0.07**

0

1.1

10

Diarrhea

5 (7%)

8 (11.6%)

0.6

0.2

1.8

23

Constipation

0

6 (8.7%)

0.08**

0

1.3

12

Abdominal pain/acidity

0

19 (27.53%)

0.03**

0

0.4***

4

Flatulence

0

9 (13.04%)

0.05**

0

0.9***

8

Upper respiratory tract infection

0

5 (7.25%)

0.09**

0

1.6

14

  1. Values are expressed as absolute number of patients (percentage) in each category
  2. Abbreviations: a treatment group, b control group, n number of patients in each category, N total number of patients in each treatment group, NNT number needed to treat, RR relative risk, RRLB relative risk lower boundary, RRUB relative risk upper boundary
  3. *P <0.01 for curcumin versus diclofenac
  4. **Clinically significant adverse event (AE) (RR <0.5)
  5. ***Statistically significant AE (95% confidence interval does not include 1)